The global CRISPR market, valued at US$2.90 billion in 2024, stood at US$3.21 billion in 2025 and is projected to advance at a resilient CAGR of 11.2% from 2025 to 2030, culminating in a forecasted valuation of US$5.47 billion by the end of the period. The growing demand for CRISPR-based gene therapies, followed by advancements in CRISPR technology, and the rising government and private investments in CRISPR technology support the market growth. The development of new vaccines for the treatment of genetic diseases and the expansion of industrial and agricultural applications are presenting strong growth opportunities for CRISPR in the coming years.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134401204
The services segment is anticipated to grow at a significant CAGR during the forecast period.
The offerings in the CRISPR market are categorized into two segments: products and services. The services segment is further divided into gRNA synthesis & cell line development, screening & validation, and other services. This services segment is experiencing a high CAGR due to the increasing demand for comprehensive and customized gene editing solutions among pharmaceutical companies, biotechnology firms, and research institutions. Additionally, the growing applications in diagnostics and therapeutics and the need for high-throughput and scalable gene editing services are driving rapid growth in this segment.
The CRISPR kits & enzymes segment is anticipated to grow at a significant CAGR during the forecast period.
The CRISPR products market is divided into three categories: CRISPR kits & enzymes, CRISPR libraries, and other products. In 2024, the CRISPR kits & enzymes segment was the largest, primarily due to their wide-ranging applications in various gene editing workflows. This includes processes such as genome modification, gene knockout, and validation studies. CRISPR kits & enzymes are essential reagents for conducting CRISPR experiments and are frequently utilized in bulk by researchers in academia, biotechnology, and the pharmaceutical industry.
The pharmaceutical & biotechnology companies segment is expected to witness the highest growth in the CRISPR services market during the forecast period.
Based on end users, the CRISPR services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. Among these, pharmaceutical & biotechnology companies are expected to experience the highest CAGR from 2025 to 2030. This growth is primarily due to their significant investments in drug discovery, gene therapy, and precision medicine. These companies heavily utilize CRISPR-based services, such as cell line engineering, high-throughput screening, and gRNA synthesis, to accelerate their research and development (R&D) processes and facilitate advancements in therapeutic options.
The Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period of 2025–2030.
The CRISPR market is divided by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest market share, driven by the presence of numerous top-ranked universities and companies, substantial funding for biotechnology and pharmaceutical research, and a highly developed healthcare system. The Asia Pacific (APAC) region is also experiencing rapid growth due to increasing healthcare demand and expanding research capabilities. Countries like China, India, and Japan are making significant advancements in biotechnology and drug discovery, which is further promoting the use of CRISPR technologies in this region.
The prominent players in the CRISPR market are Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), and GenScript (US).
Recent Developments of CRISPR Market
- In February 2023, GenScript announced the expansion of its Singapore facility to provide a premium gene synthesis service. This marks a significant expansion of the company’s advanced gene-synthesis capability and enables GenScript to provide the service levels required for novel vaccine and therapeutics development in life sciences.
- In July 2024, Agilent Technologies, Inc. (US) acquired BioVectra, Inc. (Canada), enhancing its biopharma solutions with BioVectra’s expertise in biologics and gene editing. The acquisition expanded Agilent’s capabilities in drug development and manufacturing.
- In May 2024, Merck KGaA (Germany) acquired Mirus Bio, Inc. (US), integrating Mirus Bio’s transfection technology with Merck’s bioprocessing expertise. This acquisition enhanced Merck’s capabilities in viral vector manufacturing, advancing support for cell and gene therapies.
- In March 2023, GenScript (US) announced a strategic collaboration with PersonGen-Anke Cellular Therapeutics (US) to advance cell isolation products. This partnership aimed to enhance cell therapy development and production efficiency. GenScript’s CytoSinct platform was expected to support PersonGen in reducing costs and improving R&D efficiency in cell therapy.
- In March 2023, Thermo Fisher Scientific set up a cGMP facility at the University of California, San Francisco’s Mission Bay campus, to accelerate cell therapies for cancers and other hard-to-treat diseases. The facility focuses on advancing CAR-T and CRISPR technologies, offering comprehensive drug development and manufacturing services.